Tirzepatide – Revolutionary dual incretin receptor agonist for diabetes and weight management.
Get expert medical advice and same-day prescriptions from qualified UK doctors through our secure online consultation platform.
- Professional online consultation and prescription
- Same-day service when clinically appropriate
- Secure delivery to your chosen pharmacy
Secure Telehealth Platform Trusted by Over 150,000 Patients
What is Tirzepatide?
Tirzepatide (Mounjaro) represents a breakthrough in diabetes treatment, offering superior glucose control and remarkable weight loss benefits through its unique dual incretin receptor mechanism. It’s particularly valuable for patients with type 2 diabetes who struggle with weight management.
Book an online consultation if you have type 2 diabetes that’s not optimally controlled, need advanced diabetes management, or require assessment for newer diabetes treatments. Our GPs can evaluate your diabetes care needs and determine if Tirzepatide or other advanced treatments are appropriate for your specific condition.
What is Tirzepatide used for?
- Type 2 diabetes mellitus
- Weight management in obesity
- Cardiovascular risk reduction in diabetes
- Glycemic control when other treatments insufficient
- Weight loss in diabetes patients
- Metabolic syndrome management
How does Tirzepatide work?
A dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that enhances insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety, leading to improved glucose control and significant weight loss.
Dosage and Administration
Adults
Starting dose 2.5mg once weekly by subcutaneous injection, increased every 4 weeks to 5mg, 10mg, then maximum 15mg weekly based on response and tolerance.
Children
Not currently approved for use in children under 18 years.
Important Notes
- Inject subcutaneously once weekly on the same day each week.
- Can be taken with or without food.
- Rotate injection sites (thigh, abdomen, upper arm).
- Start with low dose and increase gradually to minimize side effects.
Side Effects
Common Side Effects
- Nausea and vomiting
- Diarrhoea
- Decreased appetite
- Abdominal pain
- Constipation
- Fatigue
- Injection site reactions
- Headache
Serious Side Effects
Seek immediate medical attention if you experience:
- Pancreatitis
- Gallbladder problems
- Kidney problems
- Severe gastrointestinal reactions
- Diabetic retinopathy complications
- Severe allergic reactions
- Thyroid tumors (animal studies)
Important Warnings
- Tell your GP if you have a history of pancreatitis, gallbladder disease, or kidney problems.
- Not suitable for people with type 1 diabetes or diabetic ketoacidosis.
- May cause significant weight loss—regular monitoring required.
- Report persistent abdominal pain that may indicate pancreatitis.
- Family history of thyroid cancer is a contraindication.
Drug Interactions
Tell your GP if you're taking any of the following medications:
- Insulin and sulfonylureas—may increase hypoglycemia risk.
- Oral medications—may affect absorption due to delayed gastric emptying.
- Warfarin—may affect absorption and require monitoring.
- Generally fewer interactions than many diabetes medications.
Frequently Asked Questions
How much weight loss can I expect with Tirzepatide?
Clinical trials showed average weight loss of 15-22% of body weight over 72 weeks, which is significantly more than other diabetes medications.
How is Tirzepatide different from other diabetes injections like Semaglutide?
Tirzepatide targets both GIP and GLP-1 receptors (dual action) compared to GLP-1 only, potentially providing superior glucose control and weight loss.
Can I use Tirzepatide just for weight loss if I don't have diabetes?
In the UK, it's currently only licensed for type 2 diabetes, though trials for obesity without diabetes are ongoing.
What should I do if I miss a weekly injection?
Inject as soon as possible if within 4 days of missed dose. If more than 4 days late, skip the missed dose and resume normal schedule.
Medically Reviewed by: Mohammed Hassan - Independent Prescriber
Last Updated: 2025-01-14